Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts
Larimar Therapeutics (Nasdaq: LRMR) announced that its biomarker studies on Friedreich's ataxia will be presented at the Gordon Research Conference on Mitochondria and Chloroplasts from July 17-22, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Larimar Therapeutics (Nasdaq: LRMR) announced that its biomarker studies on Friedreich's ataxia will be presented at the Gordon Research Conference on Mitochondria and Chloroplasts from July 17-22, 2022. The study highlights differentially expressed genes between healthy individuals and those with Friedreich's ataxia, focusing on potential treatment pathways. The oral presentation will occur on July 21, 2022, at 8:40 PM ET by David Bettoun, Ph.D., the company's Vice President of Discovery and Non-clinical R&D.
Positive
- Presentation at a prominent conference highlights significant research on Friedreich's ataxia.
- Focus on developing targeted treatments aligns with the company's mission in rare diseases.
Negative
- None.
Details
News Market Reaction – LRMR
The recorded move for LRMR in the trading session of this news was -0.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BALA CYNWYD, Pa., June 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that biomarker studies that have identified genes that are differentially expressed between healthy individuals and those with Friedreich’s ataxia will be featured in an oral presentation at the upcoming Gordon Research Conference on Mitochondria and Chloroplasts during the session on “Organelle Biology Translated into Medicine and Agriculture.” The conference will take place July 17 – 22, 2022 at Mount Snow in West Dover, Vermont.
Details on the presentation are shown below.
| Presentation Title: | Identification of Differentially Expressed Genes in Friedreich’s Ataxia Patients |
| Presenting Author: | David Bettoun, Ph.D., Vice President of Discovery and Non-clinical R&D, Larimar Therapeutics |
| Presentation Date: | July 21, 2022 |
| Presentation Time: | 8:40 PM ET |
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.